A study conducted at the Los Angeles Children ‘s Hospital is providing the best treatment for a rare invasive leukemia called mixed phenotype acute leukemia (MPAL).
Daraasaddan (oo ah isku-darka tirakoobka suugaanta sayniska ee 20-ka sano) ayaa lagu ogaaday in daaweynta MPAL oo leh sunta sunta yar ay la xiriirto faa'iido cad oo ah ka-cafinta iyo badbaadada muddada-dheer. Natiijooyinkaas waxaa lagu daabacay joornaalka internetka "Leukemia" Febraayo 27, 2018.
MPAL accounts for 2% -5% of leukemia cases, which is historically difficult to treat, and the 5-year survival rate is less than 50%. The disease affects children and adults and is characterized by two common forms of leukemia: acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML).
Dhakhtarku waa inuu go'aansadaa inuu isticmaalo ALL ama AML, ama isku dar ah labada habab. Ma jiro wax la isku raacsan yahay oo ku saabsan habka ugu wanaagsan. Sababtoo ah cudurkani waa mid aad u yar, kumanaan bukaan ah ayaan lagu tijaabin bukaan socod eegtada si loo ogaado qorshaha daaweynta ugu fiican. Taabadalkeed, warbixino badan oo yar yar, go'doon, iyo badiyaa khilaafaad ayaa lagu daabacay joornaalada si weyn loogu faafiyo adduunka.
Si si fiican loo fahmo cilmi baarista jirta loona siiyo dhakhaatiirta hagitaan daaweyn oo hufan, Orgel iyo kooxda cilmi baarista ee CHLA waxay sameeyeen dib u eegis nidaamsan oo indho-indheyn ah iyo falanqeyn meta-ah ee MPAL. Kooxda ayaa ugu dambeyntii ku soo koobtay liiska 252 waraaqaha la xiriira ee ka socda 33 waddan, oo ay ku jiraan bukaanno 1,499. Raadintooda muhiimka ah: Bukaannada markii hore lagu daaweeyay DHAMMAAN (bukaanada leh sunta aadka u hooseysa) waxay ahaayeen 3 ilaa 5 jeer ay u badan tahay inay gaaraan dhammaystir buuxa marka loo eego bukaanada lagu daweeyay AML. Bukaannada helay daaweyn isku dhafan ayaa sameeyay wixii ugu xumaa.
Daraasadu waxay iftiimisay baahida muhiimka ah ee tijaabooyinka kiliinikada si loo go'aamiyo daawaynta ugu fiican ee MPAL waxayna gacan ka geysataa kor u qaadida daaweynta cudurkan naadirka ah.
